Table 2 Open in new tab Patient details...

Age

Sex

cTNM

pTNM

Surgery

Flap

Subsite

Adverse feature

CDDP dose

f/u

Clinical outcomes

Loco-regional control

cT4aN2cM0

pT4aN2cM0

Seg. man + bil. mRND

Fibula flap

Lower gum

200

12.7

DID

Yes

cT2N1M0

ypT2N2bM0

Res. buccal+ ips. mRND

Buccal mucosa

280

32.9

NED

Yes

cT4aN2bM0

ypT4aN1M0

Sub. glos + ips. mRND + con. SOHND

ALT flap

Tongue

240

21.2

DOD

cT4aN2cM0

ypT3N3bM0

Sub. Glos + bil. mRND

ALT flap

Tongue

280

18.2

DOD

cT3N2bM0

ypT4aN3bM0

Sub. glos + lat. Oro. + total laryng + bil. mRND

ALT flap

Base of tongue

Mi + E

150

11.7

DOD

Yes

cT4bN2bM0

ypT4bN3bM0

Sub. Glos + ips. mRND + con. SOHND

Cervical flap

Lower gum

Mi + E

200

23.2

AWD

rcT1N3bM0

pTisN3bM0

Par. Glos + bil. mRND

Tongue

240

19.5

NED

Yes

cT4aN1M0

ypT4aN3bM0

Sub. Glos + bil. mRND

ALT flap

Tongue

Mi + E

240

11.5

DOD

Yes

cT4aN2bM0

ypT2N2bM0

Seg. man + ips. mRND

Fibula flap

Lower gum

240

18.2

NED

Yes

Table 2

Open in new tab

Patient details and outcomes

ID	Age	PS	Sex	cTNM	pTNM	Surgery	Flap	Subsite	Adverse feature	CDDP dose	f/u	Clinical outcomes	Loco-regional control
1	70	1	M	cT4aN2cM0	pT4aN2cM0	Seg. man + bil. mRND	Fibula flap	Lower gum	Mi	200	12.7	DID	Yes
2	58	0	M	cT2N1M0	ypT2N2bM0	Res. buccal+ ips. mRND	No	Buccal mucosa	Mi	280	32.9	NED	Yes
3	68	0	F	cT4aN2bM0	ypT4aN1M0	Sub. glos + ips. mRND + con. SOHND	ALT flap	Tongue	Mi	240	21.2	DOD	No
4	50	0	F	cT4aN2cM0	ypT3N3bM0	Sub. Glos + bil. mRND	ALT flap	Tongue	E	280	18.2	DOD	No
5	79	1	M	cT3N2bM0	ypT4aN3bM0	Sub. glos + lat. Oro. + total laryng + bil. mRND	ALT flap	Base of tongue	Mi + E	150	11.7	DOD	Yes
6	65	1	M	cT4bN2bM0	ypT4bN3bM0	Sub. Glos + ips. mRND + con. SOHND	Cervical flap	Lower gum	Mi + E	200	23.2	AWD	No
7	33	0	F	rcT1N3bM0	pTisN3bM0	Par. Glos + bil. mRND	No	Tongue	E	240	19.5	NED	Yes
8	72	1	M	cT4aN1M0	ypT4aN3bM0	Sub. Glos + bil. mRND	ALT flap	Tongue	Mi + E	240	11.5	DOD	Yes
9	60	0	M	cT4aN2bM0	ypT2N2bM0	Seg. man + ips. mRND	Fibula flap	Lower gum	Mi	240	18.2	NED	Yes

ID	Age	PS	Sex	cTNM	pTNM	Surgery	Flap	Subsite	Adverse feature	CDDP dose	f/u	Clinical outcomes	Loco-regional control
1	70	1	M	cT4aN2cM0	pT4aN2cM0	Seg. man + bil. mRND	Fibula flap	Lower gum	Mi	200	12.7	DID	Yes
2	58	0	M	cT2N1M0	ypT2N2bM0	Res. buccal+ ips. mRND	No	Buccal mucosa	Mi	280	32.9	NED	Yes
3	68	0	F	cT4aN2bM0	ypT4aN1M0	Sub. glos + ips. mRND + con. SOHND	ALT flap	Tongue	Mi	240	21.2	DOD	No
4	50	0	F	cT4aN2cM0	ypT3N3bM0	Sub. Glos + bil. mRND	ALT flap	Tongue	E	280	18.2	DOD	No
5	79	1	M	cT3N2bM0	ypT4aN3bM0	Sub. glos + lat. Oro. + total laryng + bil. mRND	ALT flap	Base of tongue	Mi + E	150	11.7	DOD	Yes
6	65	1	M	cT4bN2bM0	ypT4bN3bM0	Sub. Glos + ips. mRND + con. SOHND	Cervical flap	Lower gum	Mi + E	200	23.2	AWD	No
7	33	0	F	rcT1N3bM0	pTisN3bM0	Par. Glos + bil. mRND	No	Tongue	E	240	19.5	NED	Yes
8	72	1	M	cT4aN1M0	ypT4aN3bM0	Sub. Glos + bil. mRND	ALT flap	Tongue	Mi + E	240	11.5	DOD	Yes
9	60	0	M	cT4aN2bM0	ypT2N2bM0	Seg. man + ips. mRND	Fibula flap	Lower gum	Mi	240	18.2	NED	Yes

PS, performance status; cTNM, clinical TNM stage according to UICC 8th; pTNM, pathological TNM stage according to UICC 8th; Flap, flap reconstruction; CDDP dose, total dose of cisplatin during postoperative chemoradiotherapy (mg/m²); f/u, follow-up time (month); M, male; F, female; seg. man, segmental mandibulectomy; res. of buccal, resection of buccal mucosa; sub. Glos, subtotal glossectomy; par. Glos, partial glossectomy; lat. Oro, lateral oropharyngectomy; total laryng, total laryngectomy; ips., ipsilateral; con., contralateral; bil, bilateral; mRND, modified radical neck dissection; SOHND, supraomohyoid neck dissection; ALT, anterolateral thigh; Mi, positive microscopic margins; E, extranodal extension; NED, no evidence of disease; AWD, alive with disease; DOD, died of disease; DID, died from intercurrent disease.

This Feature Is Available To Subscribers Only